The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis

Eun H. Cho, Mi Ryung Kim, Hyun Jung Kim, Do Yeon Lee, Pan Kyeom Kim, Kyung Mook Choi, Ohk Hyun Ryu, Chan Wha Kim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Diabetic nephropathy (DN) is a serious kidney complication of diabetes, and constitutes the leading cause of end-stage renal disease. The earliest clinical evidence of DN is microalbuminuria, a term which refers to the appearance of small but abnormal amounts of albumin in the urine. However, screening methods for DN, such as biomarker assays, are yet to be developed for type 2 DN. In the present study, in an attempt to identify the biomarkers for initial diagnoses of type 2 DN, the protein profiles of human sera collected from 30 microalbuminuric type 2 diabetic patients were compared with those collected from 30 normoalbuminuric type 2 diabetic patients, via 2-DE. As a result, a total of 18 spots were determined to have different protein levels in the microalbuminuric patients. Twelve spots had lower protein levels of approximately 50%, and the other six had higher levels of approximately 100-300% as compared to the spots of normoalbuminuric patients. These spots were identified with ESI-Q-TOF (ESI-quadrupole-TOF) MS. Among the identified proteins, vitamin D-binding protein (DBP) and pigment epithelium-derived factor (PEDF) were verified by Western blotting. The results of this study indicate that the DBP may be employed as diagnostic and monitoring biomarkers of type 2 DN, contingent on further study into the matter.

Original languageEnglish
Pages (from-to)352-361
Number of pages10
JournalProteomics - Clinical Applications
Volume1
Issue number4
DOIs
Publication statusPublished - 2007 Apr 1

Fingerprint

Diabetic Nephropathies
Biomarkers
Proteome
Serum
Vitamin D-Binding Protein
Proteins
Medical problems
Albumins
Assays
Carrier Proteins
Screening
Monitoring
Diabetes Complications
Chronic Kidney Failure
Western Blotting
Urine
Kidney

Keywords

  • 2-DE
  • Biomarker
  • Diabetic nephropathy
  • Microalbuminuria
  • Vitamin D-binding protein

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. / Cho, Eun H.; Kim, Mi Ryung; Kim, Hyun Jung; Lee, Do Yeon; Kim, Pan Kyeom; Choi, Kyung Mook; Ryu, Ohk Hyun; Kim, Chan Wha.

In: Proteomics - Clinical Applications, Vol. 1, No. 4, 01.04.2007, p. 352-361.

Research output: Contribution to journalArticle

Cho, Eun H. ; Kim, Mi Ryung ; Kim, Hyun Jung ; Lee, Do Yeon ; Kim, Pan Kyeom ; Choi, Kyung Mook ; Ryu, Ohk Hyun ; Kim, Chan Wha. / The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. In: Proteomics - Clinical Applications. 2007 ; Vol. 1, No. 4. pp. 352-361.
@article{e25a9183acd149abb035d1f53502446f,
title = "The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis",
abstract = "Diabetic nephropathy (DN) is a serious kidney complication of diabetes, and constitutes the leading cause of end-stage renal disease. The earliest clinical evidence of DN is microalbuminuria, a term which refers to the appearance of small but abnormal amounts of albumin in the urine. However, screening methods for DN, such as biomarker assays, are yet to be developed for type 2 DN. In the present study, in an attempt to identify the biomarkers for initial diagnoses of type 2 DN, the protein profiles of human sera collected from 30 microalbuminuric type 2 diabetic patients were compared with those collected from 30 normoalbuminuric type 2 diabetic patients, via 2-DE. As a result, a total of 18 spots were determined to have different protein levels in the microalbuminuric patients. Twelve spots had lower protein levels of approximately 50{\%}, and the other six had higher levels of approximately 100-300{\%} as compared to the spots of normoalbuminuric patients. These spots were identified with ESI-Q-TOF (ESI-quadrupole-TOF) MS. Among the identified proteins, vitamin D-binding protein (DBP) and pigment epithelium-derived factor (PEDF) were verified by Western blotting. The results of this study indicate that the DBP may be employed as diagnostic and monitoring biomarkers of type 2 DN, contingent on further study into the matter.",
keywords = "2-DE, Biomarker, Diabetic nephropathy, Microalbuminuria, Vitamin D-binding protein",
author = "Cho, {Eun H.} and Kim, {Mi Ryung} and Kim, {Hyun Jung} and Lee, {Do Yeon} and Kim, {Pan Kyeom} and Choi, {Kyung Mook} and Ryu, {Ohk Hyun} and Kim, {Chan Wha}",
year = "2007",
month = "4",
day = "1",
doi = "10.1002/prca.200600608",
language = "English",
volume = "1",
pages = "352--361",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis

AU - Cho, Eun H.

AU - Kim, Mi Ryung

AU - Kim, Hyun Jung

AU - Lee, Do Yeon

AU - Kim, Pan Kyeom

AU - Choi, Kyung Mook

AU - Ryu, Ohk Hyun

AU - Kim, Chan Wha

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Diabetic nephropathy (DN) is a serious kidney complication of diabetes, and constitutes the leading cause of end-stage renal disease. The earliest clinical evidence of DN is microalbuminuria, a term which refers to the appearance of small but abnormal amounts of albumin in the urine. However, screening methods for DN, such as biomarker assays, are yet to be developed for type 2 DN. In the present study, in an attempt to identify the biomarkers for initial diagnoses of type 2 DN, the protein profiles of human sera collected from 30 microalbuminuric type 2 diabetic patients were compared with those collected from 30 normoalbuminuric type 2 diabetic patients, via 2-DE. As a result, a total of 18 spots were determined to have different protein levels in the microalbuminuric patients. Twelve spots had lower protein levels of approximately 50%, and the other six had higher levels of approximately 100-300% as compared to the spots of normoalbuminuric patients. These spots were identified with ESI-Q-TOF (ESI-quadrupole-TOF) MS. Among the identified proteins, vitamin D-binding protein (DBP) and pigment epithelium-derived factor (PEDF) were verified by Western blotting. The results of this study indicate that the DBP may be employed as diagnostic and monitoring biomarkers of type 2 DN, contingent on further study into the matter.

AB - Diabetic nephropathy (DN) is a serious kidney complication of diabetes, and constitutes the leading cause of end-stage renal disease. The earliest clinical evidence of DN is microalbuminuria, a term which refers to the appearance of small but abnormal amounts of albumin in the urine. However, screening methods for DN, such as biomarker assays, are yet to be developed for type 2 DN. In the present study, in an attempt to identify the biomarkers for initial diagnoses of type 2 DN, the protein profiles of human sera collected from 30 microalbuminuric type 2 diabetic patients were compared with those collected from 30 normoalbuminuric type 2 diabetic patients, via 2-DE. As a result, a total of 18 spots were determined to have different protein levels in the microalbuminuric patients. Twelve spots had lower protein levels of approximately 50%, and the other six had higher levels of approximately 100-300% as compared to the spots of normoalbuminuric patients. These spots were identified with ESI-Q-TOF (ESI-quadrupole-TOF) MS. Among the identified proteins, vitamin D-binding protein (DBP) and pigment epithelium-derived factor (PEDF) were verified by Western blotting. The results of this study indicate that the DBP may be employed as diagnostic and monitoring biomarkers of type 2 DN, contingent on further study into the matter.

KW - 2-DE

KW - Biomarker

KW - Diabetic nephropathy

KW - Microalbuminuria

KW - Vitamin D-binding protein

UR - http://www.scopus.com/inward/record.url?scp=34548191121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548191121&partnerID=8YFLogxK

U2 - 10.1002/prca.200600608

DO - 10.1002/prca.200600608

M3 - Article

C2 - 21136688

AN - SCOPUS:34548191121

VL - 1

SP - 352

EP - 361

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 4

ER -